证券代码：688193 证券简称：仁度生物 公告编号：2025-037 上海仁度生物科技股份有限公司 第二届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 金用途和损害公司及全体股东利益的情况，不存在募集资金存放和使用违规的 情形。 上海仁度生物科技股份有限公司（以下简称"公司"）第二届监事会第十一 次会议于 2025 年 8 月 28 日在公司二楼会议室以现场结合通讯的表决方式召开。 会议应到监事 3 人，实到监事 3 人，出席监事占应出席人数的 100%。公司董事、 高级管理人员列席了监事会会议。本次监事会会议的召集、召开程序符合公司 章程和有关法律、法规的要求。经与会监事审议和表决，会议形成决议如下： 一、 审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 经核查，监事会认为：报告期内，公司的财务核算体制健全，会计事项的 处理、财务报表的编制及公司执行的会计制度符合有关法律法规的要求，所包 含的信息能从各个方面真实地反映出公司当期的经营管理和财务状况等事项， 财务报告中的数据 ...

证券代码：688193 证券简称：仁度生物 公告编号：2025-036 上海仁度生物科技股份有限公司 关于第二届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海仁度生物科技股份有限公司（以下简称"公司"）第二届董事会第十三 次会议于 2025 年 8 月 28 日以现场结合通讯的表决方式在公司会议室召开，会议 应到董事 7 人，实到董事 7 人，出席董事占应出席人数的 100%。公司监事、高 级管理人员列席了董事会会议。本次董事会会议的召集、召开程序符合公司章程 和有关法律、法规的要求。经与会董事审议和表决，会议形成决议如下： 一、 审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 本议案无需提交股东大会审议。 具 体 内 容 详 见 本 公 司 2025 年 8 月 30 日 于 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《2025 年半年度报告》、《2025 年半年度报告摘要》。 二、 审议通过《关于公司<2025 年半年度募集资金存放与实际使 ...

上海仁度生物科技股份有限公司2025 年半年度报告 公司代码：688193 公司简称：仁度生物 上海仁度生物科技股份有限公司 2025 年半年度报告 1 / 190 上海仁度生物科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险及应对措施，敬请查阅本 报告第三节"管理层讨论与分析"之"五、风险因素" 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人居金良、主管会计工作负责人蔡廷江及会计机构负责人（会计主管人员）蔡廷 江声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 □适用 √不适用 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及公司未来计划，发展战略等前瞻性陈述，不构成对投资者的实质承诺，敬请投 资 ...

Group 1: Epidemic Overview - The recent outbreak of Chikungunya fever in southern China has led to nearly 3,000 new cases reported in just one week, primarily in Guangdong province, affecting over ten cities [1][3] - The majority of cases are concentrated in Foshan, accounting for 95% of the total cases in Guangdong, with no severe cases or deaths reported so far [3] Group 2: Government Response and Guidelines - The National Health Commission has released the "Chikungunya Fever Diagnosis and Treatment Plan (2025 Edition)," emphasizing that the disease is preventable, controllable, and treatable [3][6] - The plan incorporates traditional Chinese medicine (TCM) approaches, highlighting the role of TCM in alleviating symptoms and promoting recovery [6] Group 3: Company Initiatives in Diagnostics and Treatment - Several listed companies in the IVD (in vitro diagnostics) sector are actively developing testing products and treatment solutions for Chikungunya fever [4][5] - Shenzhen BGI Technology Co., Ltd. has introduced the T1+ gene sequencer, which can provide comprehensive genomic analysis within 6-8 hours, aiding in rapid response to the outbreak [4] - Wanfu Biology has developed multiple Chikungunya virus detection products, creating a closed-loop system for monitoring and diagnosis [4] Group 4: Traditional Chinese Medicine Applications - TCM is being utilized for symptomatic treatment of Chikungunya fever, with specific formulations recommended for managing symptoms like fever and joint pain [6][7] - Companies such as Guangdong Yifang Pharmaceutical and Step Long Pharmaceutical are producing traditional Chinese medicines that may assist in treating Chikungunya fever [7]

Group 1: Epidemic Overview - The recent outbreak of Chikungunya fever in southern China has led to nearly 3,000 new cases reported in just one week, primarily in Guangdong province, affecting over ten cities [1][3] - The majority of cases are concentrated in Foshan, accounting for 95% of the total cases in Guangdong, with no severe cases or deaths reported so far [3] Group 2: Government Response and Guidelines - The National Health Commission has released the "Chikungunya Fever Diagnosis and Treatment Plan (2025 Edition)," emphasizing that the disease is preventable, controllable, and treatable [3][7] - The plan incorporates traditional Chinese medicine (TCM) approaches, highlighting the role of TCM in alleviating symptoms and promoting recovery [7] Group 3: Company Initiatives - Several listed companies in the IVD (in vitro diagnostics) sector are actively developing testing products and treatment solutions for Chikungunya fever [2][4] - Shenzhen BGI Technology Co., Ltd. has introduced the T1+ gene sequencer, which can rapidly analyze samples with low viral loads, aiding in precise epidemic control [2][4] - Wanfu Biology has developed multiple testing products for Chikungunya virus detection, creating a closed-loop system for rapid screening and monitoring [4] Group 4: Traditional Chinese Medicine Applications - TCM is being utilized for symptomatic treatment of Chikungunya fever, with specific formulations recommended for managing high fever and other severe symptoms [7][8] - Companies like Guangdong Yifang Pharmaceutical and others are producing traditional Chinese medicines that have shown efficacy in treating similar viral infections [8]

Market Overview - The pharmaceutical and biotechnology index increased by 2.95%, outperforming the CSI 300 index by 4.70 percentage points and the ChiNext index by 3.23 percentage points, ranking first among 31 sub-industries [4] - The Hong Kong Hang Seng Medical Health Index rose by 1.87%, surpassing the Hang Seng Index by 5.65 percentage points [4] Company R&D Progress Tracking - Recent clinical application submissions include Yimeng Biotech's DB-1419 and Hengrui Medicine's SHR-7782 injection [5] - Haisco's HSK39004 inhalation powder has also initiated its IND application [5] - Ongoing Phase III clinical trials are being conducted for Shiyao Group's SYHX1901 and Hengrui Medicine's SHR-1905, while Hengrui's HRS-7249 is in Phase II, and Kaiyin Technology's KW-040 is in Phase I [5] Current Insights - The outbreak of Chikungunya fever in Foshan has prompted the local government to initiate a Level III public health emergency response, with over 6,000 confirmed cases reported [6] - Several listed companies, including Da'an Gene, Wanfu Biology, and Shengxiang Biology, have developed PCR-based testing solutions for Chikungunya fever [6] - High-throughput sequencing solutions have been introduced by BGI and Dian Diagnostics, while antigen-antibody testing solutions are provided by companies like Aotai Biology and Rejing Biology [6] - This outbreak is expected to accelerate the accumulation of clinical data for related testing products and expedite their market approval [6] 2025 Annual Investment Strategy - The investment strategy emphasizes the need for structural selection of investment opportunities due to complex changes in population structure, policy frameworks, and economic environments [7] - The core contradiction lies in the willingness and ability to pay, leading to a focus on three payment channels within the pharmaceutical industry: hospital payments, out-of-pocket payments, and overseas payments [7] - Key investment directions include policy support for hospital payments (innovative drugs and devices), expansion of public demand (blood products, home medical devices, weight loss drug industry), and an upward cycle for overseas payments (heparin, respiratory joint inspections) [7]

Group 1 - Multiple listed companies are developing detection solutions for Chikungunya virus, including Kingmed Diagnostics, Wanfu Biology, and Shengxiang Biology [1][2] - Kingmed Diagnostics has established a comprehensive platform for serological, fluorescent PCR, and sequencing tests to accurately identify the Chikungunya virus, aiding in clinical diagnosis [1] - Wanfu Biology has responded to the recent guidelines from the National Disease Control Bureau by developing several detection products that create a closed-loop system for rapid screening, precise detection, and monitoring [1] - Shengxiang Biology has introduced a dual-platform solution combining rapid nucleic acid testing and sequencing for precise tracing, with a detection time of 25 to 45 minutes and high sensitivity [1] Group 2 - According to a report by Everbright Securities, several domestic listed companies, including Da'an Gene, Wanfu Biology, Shengxiang Biology, Zhijiang Biology, Shuoshi Biology, Mingde Biology, and Rendu Biology, have launched Chikungunya virus detection solutions [2]

Core Viewpoint - The A-share market saw a significant rise in biopharmaceutical stocks, particularly with notable gains from companies such as Nanmo Bio and Sairun Bio, following the completion of China's first Phase I clinical trial for an HIV vaccine using a modified smallpox virus as a carrier [1] Group 1: Market Performance - Biopharmaceutical stocks in the A-share market experienced a surge, with Nanmo Bio and Sairun Bio rising over 14% [1] - Tiantan Biological (600161) hit the daily limit with a 10% increase [1] - Other companies such as Zhijiang Bio, Watson Bio (300142), Rendu Bio, and Anxu Bio also saw gains [1] Group 2: Research and Development - The Chinese Center for Disease Control and Prevention's AIDS Prevention Center completed the first Phase I clinical trial for a replicative Tian Tan smallpox vaccine-based HIV vaccine [1] - The innovative research utilized the "Tian Tan strain" smallpox virus, previously used to eradicate smallpox, as a carrier [1] - The trial confirmed the safety of the vaccine and its ability to elicit an effective immune response, marking a significant advancement in HIV vaccine development in China [1]

Group 1 - The core viewpoint of the article highlights the significant progress made in HIV vaccine research in China, with the completion of the first Phase I clinical trial of a recombinant Tian Tan smallpox vaccine-based HIV vaccine [1] - The innovative approach utilizes the "Tian Tan strain" smallpox virus, previously used to eradicate smallpox, as a vector for the vaccine, demonstrating safety and the ability to elicit an effective immune response [1] - Following this announcement, the A-share market saw a surge in biopharmaceutical stocks, with notable increases including Nanmo Bio and Sairun Bio rising over 14%, and Tiantan Bio hitting the daily limit of 10% [1]

Group 1 - The A-share market saw a surge in biopharmaceutical stocks, with notable increases including Nanmo Bio and Sairun Bio rising over 14%, and Tiantan Bio hitting a 10% limit up [1] - The China CDC and other teams completed the first Phase I clinical trial of a replicative Tian Tan smallpox vaccine-based HIV vaccine, marking a significant advancement in HIV vaccine research in China [1] - The innovative approach utilized the "Tian Tan strain" smallpox virus, previously used to eradicate smallpox, to verify the safety and effective immune response of the vaccine [1]